Journal rankings · indicator year 2012
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Subfield ranking · 2012
Oncology journal rankings 2012
153 ranked journals · Subfield in Medicine
Oncology has 153 ranked journals in 2012. The median OJR rose 0.06 on 2011 to 1.01, above the world average of 1.00; Q1 starts at OJR 1.61. The top three are CA A Cancer Journal for Clinicians, Cancer Cell, and The Lancet Oncology.
Ranks and citation indicators: 2012. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2009–2011, the window the 2012 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields of Medicine (42)
- Surgery610
- Pulmonary and Respiratory Medicine245
- Public Health, Environmental and Occupational Health213
- Cardiology and Cardiovascular Medicine209
- Oncology153
- Epidemiology147
- Infectious Diseases144
- Endocrinology, Diabetes and Metabolism124
- Neurology120
- Radiology, Nuclear Medicine and Imaging112
- Physiology110
- Psychiatry and Mental health109
Show all 42 subfields
- Orthopedics and Sports Medicine85
- Ophthalmology67
- Pediatrics, Perinatology and Child Health67
- Dermatology64
- Hematology60
- Obstetrics and Gynecology55
- Rheumatology53
- Nephrology40
- Pharmacology38
- Complementary and alternative medicine37
- Reproductive Medicine37
- Geriatrics and Gerontology34
- Emergency Medicine32
- Otorhinolaryngology28
- Rehabilitation21
- Critical Care and Intensive Care Medicine20
- Pathology and Forensic Medicine20
- Hepatology16
- Genetics14
- Immunology and Allergy13
- Anesthesiology and Pain Medicine10
- Urology10
- Gastroenterology6
- Internal Medicine4
- Family Practice2
- Transplantation2
- Anatomy0
- Biochemistry0
- Health Informatics0
- Microbiology0
153 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2011. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2009–2011, the window the 2012 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2009–2011 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2003 to 2012. | Compare |
|---|---|---|---|---|---|---|---|
1CA A Cancer Journal for CliniciansOAWiley · United States | 56.47Q1 | 196.93 85.70 up from 2011 | 71 | 100% | $4,330 | ||
2Cancer CellCell Press · Netherlands | 7.11Q1 | 20.07 0.63 up from 2011 | 465 | 100% | $10,400 | ||
3The Lancet OncologyElsevier BV · United Kingdom | 6.40Q1 | 14.09 0.09 down from 2011 | 714 | 10% | $7,280 | ||
4Journal of Clinical OncologyLippincott Williams & Wilkins · United States | 5.98Q1 | 13.68 1.24 down from 2011 | 3,135 | 9% | — | ||
5Nature MedicineNature Portfolio · United States | 5.19Q1 | 10.41 0.32 down from 2011 | 1,324 | 33% | $12,690 | ||
6Journal of the National Comprehensive Cancer NetworkNational Comprehensive Cancer | 4.15Q1 | 7.48 1.30 down from 2011 | 223 | 65% | — | ||
7JNCI Journal of the National Cancer InstituteOxford University Press · United States | 4.10Q1 | 10.85 0.67 up from 2011 | 648 | 48% | $5,436 | ||
8Clinical Cancer ResearchAmerican Association for Cancer Research · United States | 3.52Q1 | 9.18 0.18 up from 2011 | 2,510 | 42% | — | ||
9Seminars in Cancer BiologyElsevier BV · United States | 3.20Q1 | 9.14 2.38 up from 2011 | 150 | 42% | $6,060 | ||
10Clinical Pharmacology & TherapeuticsWiley · United States | 2.96Q1 | 5.67 0.51 up from 2011 | 847 | 25% | $4,410 | ||
11Annals of OncologyElsevier BV · Netherlands | 2.66Q1 | 6.60 0.57 up from 2011 | 1,621 | 100% | $5,080 | ||
12CancerWiley · United States | 2.60Q1 | 5.64 0.05 up from 2011 | 2,463 | 67% | $4,790 | ||
13The OncologistOAAlphaMed Press · United Kingdom | 2.49Q1 | 5.72 0.42 up from 2011 | 567 | 97% | $3,852 | ||
14Cancer ControlOASAGE Publishing · United States | 2.49Q1 | 5.33 0.48 up from 2011 | 91 | 46% | $2,650 | ||
15Seminars in OncologyElsevier BV · United States | 2.44Q1 | 5.86 0.97 up from 2011 | 253 | 20% | $3,550 | ||
16British Journal of CancerSpringer Nature · United Kingdom | 2.38Q1 | 6.15 0.06 down from 2011 | 1,709 | 100% | $5,190 | ||
17Journal of Mammary Gland Biology and NeoplasiaSpringer Science+Business Media · United States | 2.37Q1 | 7.72 1.45 up from 2011 | 109 | 58% | $4,090 | ||
18International Journal of CancerWiley · United States | 2.30Q1 | 6.28 0.74 up from 2011 | 2,279 | 66% | $5,030 | ||
19Cancer Epidemiology Biomarkers & PreventionAmerican Association for Cancer Research · United States | 2.28Q1 | 5.89 0.65 up from 2011 | 1,176 | 37% | — | ||
20Molecular Cancer TherapeuticsAmerican Association for Cancer Research · United States | 2.25Q1 | 6.18 0.04 down from 2011 | 992 | 56% | — | ||
21Current Opinion in OncologyLippincott Williams & Wilkins · United Kingdom | 2.24Q1 | 5.14 0.27 down from 2011 | 301 | 20% | — | ||
22European Journal of CancerElsevier BV · United Kingdom | 2.12Q1 | 6.06 0.06 up from 2011 | 1,301 | 27% | $4,270 | ||
23Cancer Prevention ResearchAmerican Association for Cancer Research · United States | 2.11Q1 | 5.44 0.41 up from 2011 | 647 | 24% | — | ||
24European Journal of EpidemiologySpringer Science+Business Media · Italy | 2.02Q1 | 5.28 0.65 up from 2011 | 318 | 36% | $3,690 | ||
25Cancer DiscoveryAmerican Association for Cancer Research · United States | 2.01Q1 | 4.29no 2011 value | 160 | 20% | — | — | |
26Cancer Treatment ReviewsElsevier BV · United Kingdom | 1.99Q1 | 6.50 0.70 down from 2011 | 295 | 16% | $4,910 | ||
27JNCI MonographsOxford University Press · United Kingdom | 1.99Q1 | 4.99 1.67 up from 2011 | 73 | 96% | — | ||
28Current Treatment Options in OncologySpringer Science+Business Media · United States | 1.97Q1 | 4.24 0.42 up from 2011 | 75 | 7% | $4,890 | ||
29Journal of Hematology & OncologyOABioMed Central · United Kingdom | 1.96Q1 | 5.47 0.18 up from 2011 | 158 | 100% | $4,990 | ||
30The Cancer JournalLippincott Williams & Wilkins · United States | 1.87Q1 | 4.38 0.03 down from 2011 | 250 | 31% | — | ||
31Journal of Cancer SurvivorshipSpringer Science+Business Media · United States | 1.86Q1 | 5.02 1.31 up from 2011 | 123 | 53% | $4,790 | ||
32Diseases of the Colon & RectumLippincott Williams & Wilkins · United States | 1.85Q1 | 4.04 0.22 up from 2011 | 838 | 5% | — | ||
33Expert Opinion on Investigational DrugsTaylor & Francis · United Kingdom | 1.79Q1 | 4.48 0.60 down from 2011 | 451 | 22% | — | ||
34Critical Reviews in Oncology/HematologyElsevier BV · Netherlands | 1.73Q1 | 4.61 0.51 up from 2011 | 316 | 8% | $4,190 | ||
35Hematology/Oncology Clinics of North AmericaElsevier BV · United States | 1.73Q1 | 3.39 0.84 down from 2011 | 228 | 15% | $3,950 | ||
36Current Oncology ReportsSpringer Science+Business Media · United States | 1.69Q1 | 4.05 0.52 up from 2011 | 184 | 25% | $5,090 | ||
37BMC CancerOABioMed Central · United Kingdom | 1.68Q1 | 4.53 0.47 up from 2011 | 1,687 | 100% | $3,390 | ||
38Breast Cancer ResearchOABioMed Central · United Kingdom | 1.64Q1 | 4.45 0.12 up from 2011 | 760 | 100% | $4,190 | ||
39Archives of Pathology & Laboratory MedicineOAAmerican Medical Association · United States | 1.61Q1 | 3.48 0.01 up from 2011 | 710 | 34% | — | ||
40Cancer Causes & ControlSpringer Science+Business Media · Netherlands | 1.55Q2 | 3.99 0.53 up from 2011 | 580 | 53% | $3,890 | ||
41Psycho-OncologyWiley · United Kingdom | 1.54Q2 | 3.08 0.22 down from 2011 | 584 | 28% | $4,940 | ||
42Integrative Cancer TherapiesOASAGE Publishing · United States | 1.49Q2 | 2.79 0.09 up from 2011 | 165 | 100% | $2,650 | ||
43Clinical & Experimental MetastasisSpringer Science+Business Media · Netherlands | 1.45Q2 | 4.18 0.41 up from 2011 | 207 | 33% | $5,090 | ||
44Cancer MicroenvironmentSpringer Science+Business Media · Netherlands | 1.44Q2 | 3.95 1.62 up from 2011 | 71 | 100% | $3,860 | ||
45Cancer Immunology ImmunotherapyOASpringer Science+Business Media · Germany | 1.43Q2 | 4.36 0.30 up from 2011 | 520 | 100% | $4,590 | ||
46Supportive Care in CancerSpringer Science+Business Media · Germany | 1.38Q2 | 3.22 0.32 up from 2011 | 773 | 29% | $4,690 | ||
47CytotherapyElsevier BV · United Kingdom | 1.36Q2 | 3.57 0.33 down from 2011 | 392 | 21% | $3,300 | ||
48Journal of Inorganic BiochemistryElsevier BV · United States | 1.36Q2 | 3.44 0.01 up from 2011 | 616 | 20% | $4,220 | ||
49World Journal of Clinical OncologyOABaishideng Publishing Group · United States | 1.34Q2 | 2.83 1.35 up from 2011 | 52 | 100% | — | ||
50Future OncologyFuture Medicine · United Kingdom | 1.34Q2 | 2.98 0.10 down from 2011 | 499 | 14% | — |
Subfields of Medicine, with Oncology highlighted.
- Surgery610
- Pulmonary and Respiratory Medicine245
- Public Health, Environmental and Occupational Health213
- Cardiology and Cardiovascular Medicine209
- Oncology153
- Epidemiology147
- Infectious Diseases144
- Endocrinology, Diabetes and Metabolism124
- Neurology120
- Radiology, Nuclear Medicine and Imaging112
- Physiology110
- Psychiatry and Mental health109
- Orthopedics and Sports Medicine85
- Ophthalmology67
- Pediatrics, Perinatology and Child Health67
- Dermatology64
- Hematology60
- Obstetrics and Gynecology55
- Rheumatology53
- Nephrology40
- Pharmacology38
- Complementary and alternative medicine37
- Reproductive Medicine37
- Geriatrics and Gerontology34
- Emergency Medicine32
- Otorhinolaryngology28
- Rehabilitation21
- Critical Care and Intensive Care Medicine20
- Pathology and Forensic Medicine20
- Hepatology16
- Genetics14
- Immunology and Allergy13
- Anesthesiology and Pain Medicine10
- Urology10
- Gastroenterology6
- Internal Medicine4
- Family Practice2
- Transplantation2
- Anatomy0
- Biochemistry0
- Health Informatics0
- Microbiology0
Journals
Citations made in 2012. Corpus-wide, 75.7% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
62 additional Oncology journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2009–2011, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2012. Publication window: 2009–2011. How these summaries are calculated
- Ranked journals
- 153
- Window papers (baseline)
- 86,189 +20.9% from indicator year 2009
- Median OJR
- 1.006 +8.4% from indicator year 2009
- Rising journals (2025)
- 20
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2009–2011 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 82 | 88 | 96 | 103 | 109 | 120 | 120 | 126 | 127 | 134 | 141 | 150 | 153 | 170 | 179 | 188 | 198 | 213 | 224 | 234 | 238 | 239 | 245 | 245 | 243 | 242 | |
| Window papers (baseline) | 37,821 | 41,430 | 44,340 | 47,392 | 49,058 | 53,111 | 57,002 | 62,106 | 66,087 | 71,283 | 77,009 | 82,075 | 86,189 | 88,804 | 93,912 | 98,660 | 102,921 | 105,891 | 109,984 | 115,044 | 121,890 | 139,666 | 156,942 | 167,602 | 163,907 | 160,807 | |
| Median OJR | 0.55 | 0.62 | 0.70 | 0.799 | 0.805 | 0.831 | 0.85 | 0.90 | 0.94 | 0.93 | 1.010 | 0.95 | 1.006 | 0.974 | 0.972 | 0.967 | 0.832 | 0.84 | 0.82 | 0.79 | 0.829 | 0.830 | 0.77 | 0.750 | 0.73 | 0.748 |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.